Literature DB >> 26506836

Impact of previous cardiac surgery on long-term outcome of cavotricuspid isthmus-dependent atrial flutter ablation.

Paolo D Dallaglio1, Ignasi Anguera2, Javier Jiménez-Candil3, Rafael Peinado4, Javier García-Seara5, Mari Fe Arcocha6, Rosa Macías7, Benito Herreros8, Aurelio Quesada9, Antonio Hernández-Madrid10, Miguel Alvarez7, Andrea Di Marco2, David Filgueiras4, Roberto Matía10, Angel Cequier2, Xavier Sabaté2.   

Abstract

AIMS: The aim of this study was to determine the acute and long-term outcome of radiofrequency catheter ablation (RFCA) for cavotricuspid isthmus-dependent atrial flutter (CTI-AFL) in adults with and without previous cardiac surgery (PCS), and predictors of these outcomes. Structural alterations of the anatomical substrate of the CTI-AFL are observed in post-operative patients, and these may have an impact on the acute success of the ablation and in the long-term. METHODS AND
RESULTS: Clinical records of consecutive adults undergoing RFCA of CTI-AFL were analysed. Two main groups were considered: No PCS and PCS patients, who were further subdivided into acquired heart disease (AHD: ischaemic heart disease and valvular/mixed heart disease) and congenital heart disease [CHD: ostium secundum atrial septal defect (OS-ASD) and complex CHD]. Multivariate analysis identified clinical and procedural factors that predicted acute and long-term outcomes. A total of 666 patients (73% men, age 65 ± 12 years) were included: 307 of them with PCS. Ablation was successful in 647 patients (97%), 96% in the PCS group and 98% in the No PCS group (P = 0.13). Regression analysis showed that surgically corrected complex CHD was related to failure of the procedure [odds ratio 5.6; 95% confidence interval (CI) 1.6-18, P = 0.008]. After a follow-up of 45 ± 15 months, recurrences were observed in 90 patients (14%), more frequently in the PCS group: absolute risk of recurrence 18 vs. 10.5%, relative risk 1.71, 95% CI: 1.2-2.5, P = 0.006. Multivariate analysis indicated that the types of PCS [OS-ASD vs. No PCS: hazard ratio (HR) 2.57; 95% CI: 1.1-6.2, P = 0.03 and complex CHD vs. No PCS: HR 2.75; 95% CI: 1.41-5.48, P = 0.004], female gender (HR 1.55; 95% CI: 1.04-2.4, P = 0.048), and severe LV dysfunction (HR 1.36; 95% CI: 1.06-1.67, P = 0.04) were independent predictors of long-term recurrence.
CONCLUSION: Radiofrequency catheter ablation of CTI-AFL after surgical correction of AHD and CHD is associated with high acute success rates. The severity of the structural alterations of the underlying heart disease and consequently the type of surgical correction correlates with higher risk for recurrence. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2015. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  Atrial flutter; Cardiac surgery; Cavotricuspid isthmus; Congenital heart disease; Coronary artery disease; Radiofrequency catheter ablation

Mesh:

Year:  2015        PMID: 26506836     DOI: 10.1093/europace/euv237

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  4 in total

1.  Supraventricular Arrhythmias in Patients with Adult Congenital Heart Disease.

Authors:  Carina Blomström Lundqvist; Tatjana S Potpara; Helena Malmborg
Journal:  Arrhythm Electrophysiol Rev       Date:  2017-06

Review 2.  Atrial Fibrillation Ablation in Adults With Repaired Congenital Heart Disease.

Authors:  Marta Acena; Ignasi Anguera; Paolo D Dallaglio; Marcos Rodriguez; Xavier Sabaté
Journal:  J Atr Fibrillation       Date:  2016-02-29

Review 3.  [Catheter ablation of ventricular tachycardia in patients with structural heart disease].

Authors:  F Lindemann; A Darma; G Hindricks
Journal:  Herz       Date:  2022-03-09       Impact factor: 1.443

4.  Lone Atrial Flutter in Children and Adolescents: Is It Really "Lone"?

Authors:  Jana-K Dieks; David Backhoff; Heike E Schneider; Matthias J Müller; Ulrich Krause; Thomas Paul
Journal:  Pediatr Cardiol       Date:  2020-11-09       Impact factor: 1.655

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.